Antithymocyte globulin use for treatment of biopsy confirmed acute rejection is associated with prolonged renal allograft survival.

A. Kainz(1,2), R. Korbély(1), A. Soleiman(3), B. Mayer(4), R. Oberbauer(1,2,5)

1- Department of Nephrology, KH Elisabethinen, Linz, Austria

2- Department of Nephrology, Medical University Vienna, Austria

3- Department of Pathology, Medical University Vienna, Austria

4- emergentec biodevelopment GmbH, Vienna, Austria

5- Austrian Dialysis and Transplant Registry, Austria

 

// Tables
// Figures

Webtable 1:
Webtable 1:

Variables used for computing the propensity score of ATG use.

View PDF

Webfigure 1:
Webfigure 1:

Hazard ratio for OKT3 vs ATG useage and 95 % confidence intervals are nearly the same, when missing data are replaced by the median of the respective group.
Red lines represent the models computed with data missing, black lines represent the hazard ratio and 95 % confidence interval when missing data are replaced.

View PDF

Webtable 2:
Webtable 2:

Modification of hazard ratio for OKT3 vs. ATG usage in the automated model, which is calculated as a bivariable model

View PDF

Webtable 3:
Webtable 3:

Correlation matrix of the Schoenfeld residuals of variables used in the model for functional graft survival with followup time and rank of followup time.

View PDF

Webfigure 2:
Webfigure 2:

Schoenfeld residuals for functional graft survival.

View PDF

Webtable 4:
Webtable 4:

Correlation matrix of the Schoenfeld residuals of variables used in the model for actual graft survival with followup time and rank of followup time.

View PDF

Webfigure 3:
Webfigure 3:

Schoenfeld residuals for actual graft survival.

View PDF

Webtable 5:
Webtable 5:

Correlation matrix of the Schoenfeld residuals of variables used in the model for patient survival with followup time and rank of followup time.

View PDF

Webfigure 4:
Webfigure 4:

Schoenfeld residuals for patient survival.

View PDF

Webtable 6:
Webtable 6:

Analyses with first transplantation only.
Associations between OKT3 use and functional graft loss using different model-building strategies

View PDF

Webtable 7:
Webtable 7:

Analyses with first transplantation only.
Associations between OKT3 use and actual graft loss using different model-building strategies

View PDF

Webfigure 5:
Webfigure 5:

Analyses with first transplantation only.
Forest plot of hazard ratios for OKT3 use.

View PDF

Webtable 8:
Webtable 8:

Analyses with first transplantation only.
Associations between OKT3 use and patient mortality using different model-building strategies

View PDF

Webtable 9:
Webtable 9:

Analyses with patientes who experienced BCAR in the first three months of the first transplantation.
Associations between OKT3 use and functional graft loss using different model-building strategies

View PDF

Webtable 10:
Webtable 10:

Analyses with patientes who experienced BCAR in the first three months of the first transplantation.
Associations between OKT3 use and actual graft loss using different model-building strategies

View PDF

Webfigure 6:
Webfigure 6:

Analyses with patientes who experienced BCAR in the first three months of the first transplantation.
Forest plot of hazard ratios for OKT3 use.

View PDF

Webtable 11:
Webtable 11:

Analyses with patientes who experienced BCAR in the first three months of the first transplantation.
Associations between OKT3 use and patient mortality using different model-building strategies.

View PDF

SCIENTIFIC COLLABORATIONS